Search
A recent study found that the cell lines most commonly used for research on ovarian cancer are not the most suitable.
The U.S. Food and Drug Administration (FDA) approved 11 cancer drugs in 2024 based on significant contributions from MSK researchers.
Pediatric oncologist Julia Glade Bender talks about the challenges of treating rare childhood cancers and how personalized medicine is leading to better therapies for tumors that are especially hard to treat.
Information gleaned from a liquid biopsy may help predict how individual women with advanced breast cancer will respond to certain therapies as well as reveal genetic mutations that can impact prognosis, according to two new studies led by Memorial Sloan Kettering Cancer Center (MSK) Physician-in-Chief José Baselga and physician-scientist Sarat Chandarlapaty. The studies were presented this week at the San Antonio Breast Cancer Symposium.
The SNO Lifetime Achievement Award is given annually to a meritorious individual who has made significant contributions in neuro-oncology over their career in clinical care and/or translational or basic research.
With the creation of the Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering sets out to deliver on the promise of personalized medicine by creating better treatment options for all people with cancer.
Memorial Sloan Kettering Cancer Center (MSK) announces its most recent awards and appointments for the institution’s physicians, scientists, nurses, and staff.
Physicians and scientists from Memorial Sloan Kettering Cancer Center (MSK) will join oncology experts and members of the global cancer research community to present the latest advances in cancer during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, May 31–June 4, in Chicago.
Charles Sawyers, Chair of Memorial Sloan Kettering’s Human Oncology and Pathogenesis Program, is a recipient of the inaugural $3 million prize for groundbreaking achievements in scientific research.
Jeffrey Zwicker, MD, has been named Chief of the Hematology Service at Memorial Sloan Kettering Cancer Center (MSK). He joins MSK from Harvard University Medical School, where he was an Associate Professor of Medicine, and Beth Israel Deaconess Medical Center (BIDMC), where he served as Chief of Benign Hematology in the Division of Hematology since 2017. Dr. Zwicker succeeds MSK’s Interim Hematology Service Chief, Marcel van den Brink, MD, PhD.